NCT00623636[Secondary Source ID] - Search Results

Your saved search

Your RSS Feed

Year	Number of Results
2011	3
2012	1
2025	0

Page 1

Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia.

Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, Silberstein SD. Tepper SJ, et al. Headache. 2012 Jan;52(1):37-47. doi: 10.1111/j.1526-4610.2011.02041.x. Epub 2011 Nov 22. Headache. 2012. PMID: 22106843 Clinical Trial.

MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.

Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW. Aurora SK, et al. Headache. 2011 Apr;51(4):507-17. doi: 10.1111/j.1526-4610.2011.01869.x. Headache. 2011. PMID: 21457235 Clinical Trial.

MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.

Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. Tepper SJ, et al. Mayo Clin Proc. 2011 Oct;86(10):948-55. doi: 10.4065/mcp.2011.0093. Mayo Clin Proc. 2011. PMID: 21964172 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year